Drug Profile
Amfetamine modified release - Highland Therapeutics
Alternative Names: D-amphetamine sulfate capsules; Dexamfetamine modified release - Highland Therapeutics; Dextroamphetamine sulfate modified release - Highland Therapeutics; HLD 900; HLD-100Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Highland Therapeutics
- Developer Highland Therapeutics; Ironshore Pharmaceutical and Development
- Class Amphetamines; Behavioural disorder therapies; Sleep disorder therapies
- Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Attention-deficit hyperactivity disorder; Bulimia nervosa
Most Recent Events
- 28 Sep 2021 Discontinued - Clinical-Phase-Unknown for Bulimia nervosa in Canada (PO)
- 28 Sep 2021 Discontinued - Phase-I/II for Attention-deficit hyperactivity disorder (In adolescents, In children) in Canada (PO)
- 28 Sep 2021 Discontinued - Phase-II for Attention-deficit hyperactivity disorder (In children) in USA (PO)